$173.96 2.1%
Price vs. AI Score (Last 150 days)
Data gathered: December 6

Data Bits

Data Bits Value / Change Benchmark
Job Posts 48 2.1%
Sentiment 92 0%
Webpage traffic 37,000 -20.2%
Employee Rating 72 0%
Google Trends 22 0%
Linkedin Employees 2,281 N/A
Patents 338 0%
4chan Mentions 0% N/A
Facebook Engagement 226 49.7%
Facebook followers 135 0.7%
Stocktwits Mentions 1 0%
Stocktwits Subscribers 3,965 0%
Twitter Followers 16,316 -0% N/A
Youtube Subscribers 2,060 0%
Instagram Followers 1,277 0.1%
News Mentions 1 0%
Reddit Mentions 0%
Business outlook 71 0%

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

In the news

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

Alnylam Pharmaceuticals
Price $173.96
Target Price Sign up
Market Cap $21.5B
Dividend Yield 0.0252
Industry Biotechnology

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda
Q3 '23720M279M441M148M182M
Q2 '23289M290M-1.3M-276M-244M
Q1 '23290M225M65M-174M-143M
Q4 '22335M257M79M-207M-177M
Q3 '22264M272M-8.1M-406M-235M

Insider Transactions

Garg Pushkal filed to sell 4,345 shares at $185.3.
August 7 '23
Vaishnaw Akshay filed to sell 22,774 shares at $189.3.
August 7 '23
Greenstreet Yvonne filed to sell 35,216 shares at $189.3.
August 7 '23
Poulton Jeffrey V. filed to sell 15,873 shares at $189.3.
August 7 '23
BONNEY MICHAEL W filed to sell 16,029 shares at $187.7.
August 4 '23
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2023 AltIndex. All rights reserved.